Scholars Central

Conference abstractPublished 19 Dec 2014

CRM1 Inhibition in the treatment of cancer: Overcoming drug-resistance by CRM1 inhibitor combination therapy

Authors: Joel G Turner

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Significant progress has been made over the past several years in the treatment of multiple myeloma (MM). However patients eventually develop drug resistance and die from progressive disease. The incurable nature of MM clearly demonstrates the need for novel agents and treatments. In this presentation the author would like to summarize the use of CRM1 inhibitors both in the clinic and in the laboratory. In addition, the author will focus on his work using the CRM1 inhibitors KPT330 and KOS2462 to sensitize de novo and acquired drug-resistant MM cells to the proteosome inhibitors bortezomib (BTZ) and carfilzomib (CFZ) and to the topoisomerase II inhibitor doxorubicin (DOX). In the studies the author used both BTZ resistant human 8226 and U266 MM cell lines and their parental cell lines. When CRM1 inhibitors KPT330 and KOS2462 were used in combination with BTZ, CFZ or DOX we found that cell viability was decreased and apoptosis increased synergistically. CD138/ light chain positive MM cells derived from newly diagnose, relapsed or refractory MM patients were also made sensitive by CRM1 inhibitors to BTZ, CFZ and DOX. Mice treated with the CRM1 inhibitor KPT330 +/- BTZ or DOX had a significantly better response to combined treatment than single agents. In summary, CRM1 inhibitors KPT330 and KOS2464 sensitized drug-resistant and refractory multiple myeloma to proteosome inhibitors or topoisomerase II inhibitors in MM cell lines, animal models and ex vivo patient myeloma. These combination therapies may be effective for the treatment of refractory multiple myeloma.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Pharmacology & Biopharmaceutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Joel G Turner”